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Abstract
IMPORTANCE The prevalence of periodontitis is increased in patients with rheumatoid arthritis (RA)
and periodontopathic bacteria can citrullinate proteins. Periodontitis may, therefore, be an initiator
of RA and a target for prevention. Periodontal disease and periodontal bacteria have not been
investigated in at-risk individuals with RA autoimmunity but no arthritis.
OBJECTIVE To examine periodontal disease and periodontopathic bacteria in anti–cyclic
citrullinated protein (anti-CCP) antibody–positive at-risk individuals without arthritis.
DESIGN, SETTING, ANDPARTICIPANTS This cross-sectional study took place at a teaching hospital
from April 27, 2015, to May 8, 2017. Forty-eight anti-CCP–positive individuals without arthritis (CCP+
at-risk) were recruited nationally. Twenty-six patients with early RA (ERA) and 32 healthy control
individuals were recruited locally. Data were analyzed between June 1, 2017, and December 1, 2017.
INTERVENTIONS Periodontal assessment and examination of joints using ultrasonography.
MAINOUTCOMESANDMEASURES Prevalence of diseased periodontal sites, clinical periodontitis,
and periodontal inflamed surface area in CCP+ at-risk individuals compared with patients with ERA
and healthy individuals matched for age and smoking. Paired-end sequencing of DNA from
subgingival plaque from diseased and healthy periodontal sites was performed and DNAwas profiled
and analyzed.
RESULTS A total of 48 CCP+ at-risk individuals (mean [SD] age, 51.9 [11.4] years; 31 [65%] female),
26 patients with ERA (mean [SD] age, 54.4 [16.7] years; 14 [54%] female), and 32 healthy individuals
(mean [SD] age, 49.4 [15.3] years; 19 [59%] female) were recruited. Of 48 CCP+ at-risk individuals,
46 had no joint inflammation on ultrasonography. Thirty-five CCP+ at-risk individuals (73%), 12
healthy individuals (38%), and 14 patients with ERA (54%) had clinical periodontitis. Themedian
(interquartile range) percentage of periodontal sites with disease was greater in CCP+ at-risk
individuals compared with healthy individuals (3.3% [0%-11.3%] vs 0% [0%-0.7%]) and similar to
patients with ERA (1.1% [0%-13.1%]). Median (interquartile range) periodontal inflamed surface area
was higher in CCP+ at-risk individuals comparedwith healthy individuals (221mm2 [81-504mm2] vs
40 mm2 [12-205 mm2]). Patients with CCP+ at-risk had increased relative abundance of
Porphyromonas gingivalis (but not Aggregatibacter actinomycetemcomitans) at healthy periodontal
sites comparedwith healthy individuals (effect size, 3.00; 95%CI, 1.71-4.29) and patients with ERA
(effect size, 2.14; 95% CI, 0.77-3.52).
(continued)
Key Points
Question What is the prevalence of
periodontal disease and citrullinating
periodontopathic bacteria in anti–cyclic
citrullinated protein–positive at-risk
individuals (CCP+ at-risk) comparedwith
a healthy control group and patients
with early rheumatoid arthritis (RA)?
Findings This cross-sectional study
identified an increased prevalence of
periodontal disease sites, clinical
periodontitis, and periodontal inflamed
surface area in CCP+ at-risk individuals
and those with early RA compared with
a control group. Results showed that
CCP+ at-risk individuals had increased
abundance of Porphyromonas gingivalis
at healthy periodontal sites compared
with the control group and patients with
early RA.
Meaning In individuals at risk of RA,
periodontitis and P gingivaliswere
increased before joint disease andmay
be a target for prevention.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE This study found increased prevalence of periodontitis and P
gingivalis in CCP+ at-risk individuals. This suggests periodontitis and P gingivalis are associated with
disease initiation and could be targets for preventive interventions in RA.
JAMA Network Open. 2019;2(6):e195394. doi:10.1001/jamanetworkopen.2019.5394
Introduction
Autoantibodies associated with rheumatoid arthritis (RA) can be detected in the serum years before
patients develop joint inflammation,1-3 suggesting the jointsmay be a target rather than the primary
cause of this disease. Such observations suggest a preclinical phase of RA and, importantly, raise the
possibility of disease prevention. The enrichment of serum IgA anticitrullinated protein antibodies
(ACPA) in individuals at risk of RA suggests mucosal sites (eg, oral mucosa) may be important in the
earliest phase of RA.4,5 There is good evidence that periodontitis and RA are clinically associated.6-8
Furthermore, periodontitis is associated with a specific bacterial signature characterized by the
increased abundance of the pathogenic organism Porphyromonas gingivalis alongside a community
of other, predominantly anaerobic, organisms.9 Porphyromonas gingivalis is capable of citrullinating
local antigens by virtue of its peptidylarginine deiminase enzyme.10 In a putative etiological model,
virulent strains of P gingivalis at inflamed periodontal sites generate novel citrullinated antigens that
trigger a mucosal immune response in certain individuals, possibly those with genetic
predispositions.11 Recent data suggest the periodontopathic bacterium Aggregatibacter
actinomycetemcomitansmay also directly induce neutrophil citrullination at the periodontium12 and
therefore potentially initiate ACPA.
Despite these observations, to our knowledge, periodontitis and citrullinating bacteria have not
been described in individuals at risk of RA.We sought to comprehensivelymeasure periodontitis and
the abundance of key citrullinating bacteria in individuals who were ACPA positive (ie, individuals
positive for anti–cyclic citrullinated protein [CCP] without synovitis and at risk of RA), patients with
anti-CCP–positive early RA (ERA), and healthy control individuals. We hypothesized that (1)
periodontitis would be similarly increased in CCP+ at-risk individuals and those with ERA compared
with healthy individuals and (2) there would be an increased abundance of citrullinating
periodontopathic bacteria in CCP+ at-risk individuals and patients with ERA compared with healthy
individuals.
Methods
Design
A cross-sectional study of periodontal and clinical parameters was performed in CCP+ at-risk
individuals, patients with ERA, and healthy individuals between April 27, 2015, andMay 8, 2017. In
this exploratory study, we aimed for 30 participants per group, in linewith recommendations for pilot
studies. Groups were approximately frequencymatched during recruitment for age, sex, and
smoking status. After 20 CCP+ at-risk individuals, 20 healthy individuals, and 10 patients with ERA
were recruited, demographic and smoking data were reviewed. Approximate frequency matching
was performed to recruit remaining healthy individuals and patients with ERAwithin the age range of
31 to 70 years and to recruit balanced numbers within the tertiles of age calculated in the first 20
CCP+ at-risk individual (first and third tertiles 52 and 60 years, respectively). We approximately
matched the proportion of participants who had ever smoked, which was 60% in the first 20 CCP+
at-risk individuals.
A shotgunmetagenomic analysis was performed on subgingival plaque samples collected
during the periodontal assessments.
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Ethical approval for this study was provided by the National Research Ethics Service Committee
Yorkshire and theHumber, LeedsWest.Written informed consentwas received from all participants.
This study followed the Strengthening theReporting ofObservational Studies in Epidemiology (STROBE)
reporting guideline.13
Clinical Participants
Anti-CCP–positive at-risk individuals with musculoskeletal symptoms but no clinical synovitis,
patients with ERA, and asymptomatic healthy individuals were recruited at Chapel Allerton Hospital,
Leeds, United Kingdom.
We recruited CCP+ at-risk participants from the Leeds at-risk cohort.14,15 Patients older than 18
years presenting to general practitioners or other health professionals with new-onset
musculoskeletal symptoms but no clinical synovitis were invited to participate. Primary care
recruitment was adopted nationally by the UK Primary Care Clinical Research Network. Anti-CCP
testing was performed centrally using the Bioplex 2200 kit (BioRad). Those with a positive test result
were invited to a dedicated research clinic in Leedswhere recruitment for this studywas undertaken.
Patients from the Leeds early arthritis clinic who were anti-CCP–positive but did not have clinical
synovitis were also recruited. Patients with ERAwere all anti-CCP–positive and within the first 3
months of disease-modifying antirheumatic drug (DMARD) therapy. Control participants had no joint
disease or history of inflammatory arthritis (and no affected first-degree relatives). Control
individuals included coworkers at the University of Leeds (eg, academics, administrative workers,
laboratory staff, cleaning staff) and people from the local community (eg, lay members of the Leeds
Biomedical Research Centre Patient and Public Involvement group, their contacts, and local
community groups). Control participants were typical of the general population with a range of
socioeconomic groups represented.
Demographic details and a serum IgG anti-CCP2 test (Immunocap; Phadia) were taken at the
time of the periodontal assessment.
Periodontal Assessment
Periodontal assessments were performed at Chapel Allerton Hospital, Leeds. Periodontal status was
assessed by 3 experienced dentists (V.C., A.S., and A.T.). Dentists were blinded to the RA status of
the participants. A full-mouth examination of 6 sites on each natural tooth (recorded as a 6-point
pocket chart) was performed on each participant. The 6 sites measured were the 4 corners of the
tooth and themidpoint between the buccal and lingual aspects of the tooth. The following
parameters were recorded at each available dental site: probing pocket depth (PPD) (millimeters),
clinical attachment level (CAL) (millimeters), and presence of bleeding on probing (BOP) (indicated
as present or absent). The PCP10 periodontal probe (Hu-Friedy) was used for assessment of BOP and
PPD. Measurements of PPDwere taken along the vertical axis of the tooth at each site using
approximately 0.25 N of force.
Periodontal disease sites were determined according to the recent update to the 1999
American Academy of Periodontology Classification of Periodontal Diseases and Conditions.16 To
ensure high sensitivity, thresholds for CAL and PPDwere deliberately set so that sites with mild,
moderate, and severe periodontitis would all be captured. Periodontal sites with 2mm or greater
CAL and 4mm or greater PPDwere defined as periodontitis sites (PDD) and considered to represent
sites of current or past (including treated) periodontitis. Periodontal sites with 2mmor greater CAL,
4 mm or greater PPD, and BOP were defined as active PDD and considered to represent current
active periodontitis.
In addition to these parameters, dentists also classified all participants according to overall
clinical periodontal status. The periodontal medical record for each participant was reviewed by the
3 dentists who were blinded to all patient details. In each case, clinical periodontal status was agreed
by consensus and was classified as follows: (1) healthy (no periodontitis or gingivitis), (2) gingivitis
only (no periodontitis), or (3) periodontitis with or without gingivitis. Classification was based on
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clinical judgment and the update to the 1999 American Academy of Periodontology Classification of
Periodontal Diseases and Conditions,16 taking into account the distribution, extent, and severity of
periodontitis and also the need for treatment.
Periodontal Inflamed Surface Area
To quantify the total burden of periodontal inflammation, the total periodontal inflamed surface area
(PISA)was calculated for each participant fromPPD and CALmeasurements at each dental site using
the method described by Nesse et al.17 This index has been proposed as a way of more accurately
quantifying inflamed periodontal tissues.17
UltrasonographyAssessment
Ultrasonography (US) evaluation was performed on all CCP+ at-risk individuals by 2 experienced
musculoskeletal sonographers (J.L.N. and L.H.). A standardized 38-joint US protocol was used
(eAppendix 1 in the Supplement shows full details). Scans were performed using a Logiq E9machine
(General Electric) using a 15-6MHz transducer. Power Doppler (PD) signal was assessed using a pulse
repetition frequency set between 0.7 and 1.0 KHz, mediumwall filter, and gain adjusted until
background noise was suppressed. Doppler frequency was 10MHz. Scoring of gray scale and PD
synovitis was according to the European League Against Rheumatism OutcomeMeasures in
Rheumatology scoring system.18,19
Subgingival Plaque Collection
Healthy and diseased periodontal sites suitable for subgingival plaque collection were identified by
dentists during the periodontal examination. Supragingival plaque was removed with cotton-wool
pledgets prior to sample collection (eAppendix 2 in the Supplement).
DNAExtraction, Library Preparation, and Sequencing
Subgingival plaque samples were thawed on ice from −80 °C. All diseased site samples were pooled
and all healthy site samples were pooled for each participant. We extracted DNA from pooled
samples using the UltraCleanMicrobial DNA Isolation Kit (Qiagen) as per manufacturer’s instructions
and quantified by using PicoGreen dsDNAReagent and Kits (Thermo Fisher Scientific) (eAppendix 2
in the Supplement).
The DNAwas sheared to 200 base pairs (bp) in a small glass vial (microTUBE AFA Fiber Pre-Slit
Snap-Cap 6 × 16 mm) by using a S220 Focused-ultrasonicator (Covaris). The size distribution of
4-fold diluted samples was evaluated on the Agilent 2200 TapeStation controlled by Agilent 2200
TapeStation Software A.01.05, using the Agilent High Sensitivity D1000 ScreenTape and Reagents.
Depending on the concentration of sheared DNA in the samples, either NEBNext Ultra DNA
Library Prep Kit for Illumina or NEBNext Ultra II DNA Library Prep Kit for Illumina (New England
Biolabs) was used for library construction, including end preparation, adaptor ligation, and
polymerase chain reaction enrichment. AxyPrep Mag PCR Clean-up beads (Corning) were used for
the clean-up steps during and after the library preparation to remove unincorporated adaptors,
primers, adaptor dimers, primer dimers, and other contaminants. The size distribution and the
quantity of the DNA libraries were checked using themethod described. We pooled DNA libraries
taggedwith different index primers together and paired-end sequenced on the Hiseq 3000machine
(Illumina).
ShotgunMetagenomic Data Processing
Sequence data were uploaded to theMG-RASTmetagenomics analysis pipeline (version 4.03) for
quality processing and basic taxonomic analysis.20 Low-quality regions (bases with quality scores
<15) and reads shorter than 15 bp were discarded. Artificial replicate sequences and host-specific
species sequences (eg, plant, human, or mouse) were also removed. Taxonomic abundance profiles
at species level were generated by annotation against the RefSeq database housed within MG-RAST
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with the threshold of 95% identity21 using representative hit strategy. Abundance profiles for P
gingivalis, A actinomycetemcomitans, and a control species, Filifactor alocis, were selected and
extracted for analysis. We selected F alocis because it is a periodontal pathogenwith no known ability
to induce citrullination.
Statistical Analysis
Descriptive statistics were used for the analysis of demographic and periodontal characteristics. For
continuous data, median and interquartile range (IQR) were presented and Kruskal-Wallis tests were
used to compare demographic and periodontal parameters (including PISA) between participant
groups. Where significant differences were found for a periodontal parameter, post hoc testing was
then performed using Bonferroni correction with a Dunn test. For categorical data (ie, clinical
periodontal classification), χ2, or Fisher exact test where appropriate, was used to compare
participant groups. The statistical significance level was set at .05 using 2-sided tests. Spearman ρ
correlation was used to assess for associations.
For the analysis of the 3 periodontal pathogens, raw count data of each species (P gingivalis, A
actinomycetemcomitans, and F alocis) were normalized and compared between different groups
using the DESeq2 package (parameters: test = “Wald” and fitType = “parametric”) in R statistical
software version 3.5.1 (R Project for Statistical Computing).22 P values were adjusted for multiple
testing using false-discovery rate correction. A pseudocount of 0.5 was added to the normalized
count to allow for log scale plotting. Effect sizes and standard errors were calculated using DESeq2
based on the negative binomial (gamma-Poisson) distribution.
Results
Baseline Characteristics
Forty-eight CCP+ at-risk individuals (mean [SD] age, 51.9 [11.4] years; 31 [65%] female), 26 patients
with ERA (mean [SD] age, 54.4 [16.7] years; 14 [54%] female), and 32 healthy individuals (mean [SD]
age, 49.4 [15.3] years; 19 [59%] female) were included. Groups were balanced for age, sex, and
smoking status (Table 1). Of 26 patients with ERA, 10 (38%) were DMARD naive. Patients with ERA
who had commenced DMARD therapy were all receiving monotherapy with a median duration of
only 2 weeks; 1 patient had commenced sulfasalazine and the remainder, methotrexate. No CCP+
at-risk individuals or healthy individuals had received DMARDs.
All CCP+ at-risk individuals and patients with ERA had tested positive for serum IgG anti-CCP2
antibodies using the Bioplex 2200 kit (BioRad) (titer3 × upper limit of normal range) when they
were recruited to the study. Of these 83 participants, 5 (6%) had a negative serum IgG anti-CCP2 test
result using the Immunocap kit (Phadia) (Table 1) at the time of periodontal assessment.
Periodontal Assessment
The percentage of periodontal sites with CAL 2mm or greater, PPD 4mmor greater, BOP, PDD, and
active PDD were all greater in anti-CCP+ at-risk individuals compared with healthy individuals
Table 1. Baseline Characteristics of Study Participants According to RA Statusa
Variable
No. (%)
Healthy Controls (n = 32) CCP+ At-Risk (n = 48) Early RA (n = 26)
Anti-CCP positive 0 44 (92) 25 (96)
Age, mean (SD), y 49.4 (15.3) 51.9 (11.4) 54.4 (16.7)
Female 19 (59) 31 (65) 14 (54)
Current smoker 6 (19) 12 (25) 4 (15)
Former smoker 12 (38) 19 (40) 13 (50)
Current disease-modifying
antirheumatic drugs
0 0 16 (62)
Abbreviations: CCP, cyclic citrullinated peptide; CCP+,
positive for CCP; RA, rheumatoid arthritis.
a Groups were balanced for age, sex, and
smoking status.
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(Table 2). In contrast, there were no differences in any of these parameters between anti-CCP+
at-risk individuals and patients with ERA. The number of missing teeth was higher in patients with
ERA comparedwith healthy individuals, likely reflecting the highermean age in this group (54 and 49
years, respectively).
Overall clinical periodontal status of all participants is shown in Table 3. Dentists classified 35 of
48 CCP+ at-risk individuals (73%) as having periodontitis, comparedwith 12 of 32 healthy individuals
(38%) (difference, 35%; 95% CI, 13%-53%; P = .02). The median (interquartile range) percentage
of periodontal sites with disease was greater in CCP+ at-risk individuals compared with healthy
individuals (3.3% [0%-11.3%] vs 0% [0%-0.7%]). Rates of periodontitis did not show difference in
prevalence between CCP+ at-risk participants and patients with ERA (1.1% [0%-13.1%]) (difference,
19%; 95% CI, −3% to 40%; P = .10).
Periodontal Inflamed Surface Area
Median (IQR) PISA in CCP+ at-risk individuals was 221 mm2 (81-504 mm2) compared with 40mm2
(12-205 mm2) in healthy individuals and 116 mm2 (25-269 mm2) in patients with ERA (P = .006;
Kruskal-Wallis test), indicating higher total periodontal inflammation in CCP+ at-risk individuals
compared with healthy participants (P = .002) (eFigure in the Supplement).
Ultrasonographic Assessment
All CCP+ at-risk individuals underwent US assessment. Synovitis was defined as the presence of gray
scale synovial hypertrophy greater than or equal to 1 and PD signal greater than or equal to 1 (gray
scale1 and PD1) at the same joint. Of 48 CCP+ at-risk individuals, 46 (96%) had no US synovitis,
Table 2. Periodontal Assessments According to RA Status
Variable
Median (IQR)
P Valuea
Healthy Controls
(n = 32)
CCP+ At-Risk
(n = 48) Early RA (n = 26)
Missing teeth, No. 5 (3-8.5) 6 (4-14.5) 12 (5-24)b .03
Sites with disease, %
Clinical attachment level
≥2 mm
9 (3-18.1) 15.1 (6.3-51.3) 25.0 (7.1-64.7) .06
Pocket depth ≥4 mm 0.6 (0-5.8) 11.4 (1.9-18.8)c 7.2 (0-20.1) .005
Bleeding on probing 8.6 (1.9-16.7) 30.0 (8.6-46.3)c 19.0 (6.8-37.8) .007
Periodontal diseased 0 (0-0.7) 3.3 (0-11.3)c 1.1 (0-13.1) .001
Active periodontal diseased 0 (0-0.6) 1.9 (0-5.8)c 1.1 (0-6.6) .001
Abbreviations: CCP+, positive for cyclic citrullinated peptide; IQR, interquartile range; RA, rheumatoid arthritis.
a P value indicates comparison across all 3 groups (Kruskal-Wallis tests).
b For significant results, Bonferroni correction with Dunn post hoc pairwise comparison is shown: early RA vs healthy
controls, P = .01.
c For significant results, Bonferroni correction with Dunn post hoc pairwise comparison is shown: CCP+ at-risk vs healthy
controls, P = .004 for percentage of sites with pocket depth 4 mm or greater, P = .002 for percentage of sites with
bleeding on probing, P = .01 for percentage of sites with periodontal disease, and P = .005 for percentage of sites with
active periodontal disease.
d We defined periodontal disease as clinical attachment level 2 mm or greater and pocket depth 4 mm or greater at the
same site.
Table 3. Overall Clinical Periodontal Status According to Rheumatoid Arthritis Status
Patient Group
Periodontal Status, No. (%)
Healthya Gingivitisb Periodontitisc
Healthy controls (n = 32) 10 (31) 10 (31) 12 (38)
Anti–cyclic citrullinated peptide–positive at-risk (n = 48) 2 (4) 11 (23) 35 (73)d
Early rheumatoid arthritis (n = 26) 3 (12) 9 (35) 14 (54)
Total (N = 106) 15 (14) 30 (28) 61 (58)
a No periodontitis or gingivitis.
b Gingivitis without periodontitis.
c Periodontitis with or without gingivitis.
d Anti–cyclic citrullinated peptide–positive at-risk vs
healthy controls, P < .001 (Fisher exact test).
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suggesting the absence of both clinical and subclinical joint inflammation in these subjects. Of the 2
patients who had US synovitis, 1 had synovitis in both first metatarsophalangeal joints and the other
in both wrist joints.
Three Periodontal Pathogens Selected From the ShotgunMetagenomes
The abundance of P gingivalis, A actinomycetemcomitans, and F alocis at healthy and diseased
periodontal sites was compared according to RA status. Read counts of P gingivalis, A
actinomycetemcomitans, and F alociswere generated fromMG-RAST (RefSeq database with 95%
identity) and normalized by DESeq2. At healthy periodontal sites, there was a greater abundance of
P gingivalis in CCP+ at-risk individuals compared with healthy participants (effect size = 3.00; 95%
CI, 1.71-4.29; P < .001 [Wald test]) and patients with ERA (effect size = 2.14; 95% CI, 0.77-3.52;
P = .002 [Wald test]) (Figure). Interestingly, at diseased periodontal sites, both CCP+ at-risk and
healthy participants had a greater abundance of P gingivalis compared with patients with ERA (effect
size = 5.12; 95% CI, 3.34-6.90 and 4.60; 95% CI, 2.54-6.66; P < .001, respectively). There were no
differences in the abundance of A actinomycetemcomitans or F alocis according to RA status at either
healthy or diseased periodontal sites.
Discussion
In this exploratory cross-sectional study, we have identified an increased prevalence of periodontal
disease and periodontal inflammation in CCP+ at-risk individuals without joint inflammation.
Furthermore, we identified an increased abundance of the periodontopathic bacterium P gingivalis
at the healthy periodontal sites of CCP+ at-risk participants compared with control individuals and
patients with ERA.
Figure. Abundance of Periodontal Bacteria at Diseased and Healthy Dental Sites According to Rheumatoid Arthritis (RA) Status
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The abundance of Aggregatibacter actinomycetemcomitans, Filifactor alocis, and
Porphyromonas gingivalis compared between groups using theWald test. CCP+ indicates
individuals positive for anti–cyclic citrullinated peptide antibodies; HC, healthy control.
a Adjusted P value <.001.
b Adjusted P value <.05.
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Several observational studies7,8,23-30 and a recentmeta-analysis6 have confirmed an association
between periodontal disease and established RA. However, whether or not periodontal disease is
truly a trigger for inflammatory arthritis cannot be assessed in patients who have already developed
RA. In the current study, we performed comprehensive periodontal examination, using quantitative
periodontal measurement, overall clinical periodontal status, and total periodontal inflammatory
burden (by PISA) in at-risk participants with anti-CCP antibodies but no clinical or subclinical
synovitis. We found an increased prevalence of periodontal disease sites and overall clinical
periodontitis as well as an increased PISA in CCP+ at-risk individuals compared with control
individuals matched for age and smoking status. The presence of high-titer serum ACPA in these
individuals indicates a break in tolerance and the development of RA-related systemic autoimmunity.
Prospective data from the CCP+ at-risk cohort suggests that while not all these individuals can be
considered to be pre-RA, somewill go on to develop clinical arthritis and RA.15 This suggests
periodontal inflammation may precede joint inflammation in the development of RA and supports
the concept of the periodontium as amucosal site of disease initiation. These findings are in line with
a recent study31 showing a higher frequency and greater severity of periodontal disease in first-
degree relatives of patients with RA, although in that study, only 9% of first-degree relatives with
periodontitis were anti-CCP positive.
Themicrobiome in periodontal disease is distinct from that seen in periodontal health, with an
increased abundance of pathogenic bacterial communities.32,33 Porphyromonas gingivalis is a key
component of the so-called red complex of gram-negative bacteria associated with periodontal
disease.9 It has been hypothesized that P gingivalis, through posttranslational citrullination of
periodontal mucosal proteins, may provide an antigenic source for ACPA in RA.11 A recent study34
showed oral priming with P gingivalis can trigger an erosive ACPA-positive arthritis in an in vivo
animal model. In the current study, we found an increased abundance of P gingivalis in subgingival
plaque from the healthy periodontal sites of CCP+ at-risk participants compared with healthy
individuals and patients with ERA. This association was not seen at diseased periodontal sites where
P gingivaliswas identified at similar levels in CCP+ at-risk and healthy participants. The reason for
the lower abundance of P gingivalis at diseased sites in patients with ERA compared with the other
groups is not fully clear, but this may be due to an early effect of therapy; 62% of these patients were
receiving DMARDs and most had also received corticosteroids. It is possible that these treatments
may have had an early influence on the periodontal microbiome. As periodontitis may be caused by a
dysregulated inflammatory response initiated by the biofilm, it is possible that immunomodulatory
therapies could have a direct effect on periodontal inflammation, with consequent effects on the
microbiome. Also, DMARDs are believed to have antimicrobial properties.35-37 It is possible that P
gingivalismay be affected in this way, and this would be an interesting area to explore in future work.
Interestingly, a recent study found evidence of dysbiosis of the subgingival microbiome in
periodontally healthy patients with RA compared with controls, suggesting RAmay be associated
with changes to the periodontal microbiome independently of periodontal inflammation.38
Abundance of P gingivaliswas no different between groups in that study, whichmay be expected, as
the patients did not have periodontitis. In contrast, in the current study, P gingivaliswas enriched at
the periodontally healthy sites of CCP+ at-risk participants, the majority of whom also had
periodontal disease sites. It is possible that the dysbiosis related to periodontitis has a broader effect
specifically in CCP+ at-risk individuals, leading to dysbiosis at distant healthy periodontal sites. Of
note, this association was not seen for A actinomycetemcomitans or F alocis, suggesting P gingivalis
may be especially significant in CCP+ at risk. While A actinomycetemcomitans has been shown to be
capable of citrullination,12 it is particularly associatedwith aggressive forms of periodontitis that were
not seen in our participants.39
Limitations
This study is limited by a relatively small sample size; CCP+ at-risk individuals are difficult to identify
and our patients have been recruited from a national primary care study. Owing to frequency
JAMANetworkOpen | Rheumatology Periodontal Disease and Bacteria in Anti-CCP Antibody–Positive Adults Without Arthritis
JAMA Network Open. 2019;2(6):e195394. doi:10.1001/jamanetworkopen.2019.5394 (Reprinted) June 7, 2019 8/12
Downloaded From: https://jamanetwork.com/ by a University of Leeds User  on 06/11/2019
matching during the recruitment period, the final group numbers were unequal; despite the planned
number of participants being exceeded, fewer patients were identified and recruited in the healthy
control group and ERA group compared with the CCP+ at-risk group. Some individuals from all
groups declined study participation. Unfortunately, details of eligible participants who declined in
each group are not available. It is possible that this self-selectionmay have introduced bias. However,
a participant survey conducted prior to periodontal assessment suggests no difference in access to
dental care or self-reported oral symptoms between CCP+ at-risk and healthy control groups
(eAppendix 3 and the eTable in the Supplement). Although participant groups were matched for
smoking status, we did not match for diabetes, which is also associated with periodontal disease.
However, the prevalence of diabetes in our participants was low and unlikely to have influenced the
data (eAppendix 4 in the Supplement). We acknowledge that other rare systemic conditions are
associated with periodontal disease (eg, neutrophil disorders, epidermolysis bullosa, Ehlers-Danlos
syndrome, hematological malignant neoplasms).40 We were not aware of our participants being
affected by these conditions, but they were not specifically excluded. These limitations mean that
the findings of this studymust be considered as exploratory. These data should be validated in other
cohorts, and longitudinal follow-upwill be important to assesswhether periodontal disease predicts
the onset of clinical arthritis in CCP+ at-risk individuals.
Conclusions
This study is the first, to our knowledge, to demonstrate an increased prevalence of periodontal
disease together with an increased abundance of P gingivalis in anti-CCP–positive individuals at risk
of RA. These data suggest periodontal inflammation and the enrichment of P gingivalismay precede
joint inflammation in RA and support an association between these risk factors and disease initiation.
This study adds to an emerging evidence base linking periodontal and systemic disease and,
therefore, further highlights the potential importance of improving dental health and reducing the
burden of periodontal disease on the risk of chronic systemic diseases such as RA. Importantly, these
findings suggest periodontal inflammationmay be a legitimate target to explore for preventive
intervention in RA.
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